How to Help Your Patients Find Disulfiram in Stock: A Provider's Guide

For patients in alcohol use disorder (AUD) recovery, disulfiram isn't just a medication — it's a central component of their sobriety strategy. When a patient calls your office unable to find it at any nearby pharmacy, they're not just frustrated. They may be frightened, at increased relapse risk, and unsure what to do.

This guide gives you a practical, step-by-step approach to help your patients navigate the ongoing disulfiram shortage — covering pharmacy search strategies, prescription adjustments, and clinical alternatives.

Step 1: Confirm the Shortage Is Affecting Your Patient

Before assuming a full shortage, verify a few things:

• Is the patient being denied the 500 mg or 250 mg strength? The 500 mg presentations are more affected.
• Has the patient checked more than one pharmacy? Availability varies by manufacturer per pharmacy.
• Has the patient checked independent pharmacies or compounding pharmacies? These often carry different manufacturer inventory.

Step 2: Consider a 250 mg Prescription Adjustment

If the 500 mg presentation is unavailable but the patient needs that dose, consider updating the prescription to 250 mg tablets with a quantity of 60 (two per day) for a 30-day supply. The 250 mg strength is more widely available in 2026 and this approach maintains the patient's therapeutic dose without interruption.

Note on insurance: Some plans may require prior authorization for increased quantity, even if the total daily dose is the same. Alert your MA or billing staff when issuing these prescriptions.

Step 3: Direct Patients to medfinder

Rather than having your staff make pharmacy calls, direct patients to medfinder.com/providers. medfinder contacts pharmacies near the patient to find which ones have their medication in stock, then texts the results directly to the patient. This saves your staff time and gives patients an immediate action they can take on their own.

Step 4: Explore Compounding as an Option

In cases where commercial disulfiram is truly inaccessible in a patient's area, a licensed 503A compounding pharmacy may be able to prepare disulfiram capsules or tablets. Key considerations for compounded disulfiram:

• The prescription must explicitly authorize compounding; a standard generic Rx may not suffice.
• Insurance typically does not cover compounded medications — expect out-of-pocket costs of $50-$150/month.
• The active pharmaceutical ingredient (API) — disulfiram USP — is commercially sourced and the same as in commercial tablets.

Step 5: Clinical Transition to Naltrexone or Acamprosate

If all avenues to locate disulfiram are exhausted, transitioning to a first-line agent is appropriate. Both naltrexone and acamprosate have robust evidence bases and are endorsed by the APA (2018), SAMHSA, and NIAAA as first-line pharmacotherapy for AUD.

Naltrexone transition: Ensure the patient is not using opioids (contraindicated). Start oral naltrexone 25 mg/day for 3 days, then 50 mg/day maintenance. Consider injectable Vivitrol (380 mg/month) for patients with adherence concerns.

Acamprosate transition: Initiate after abstinence is established. Start at 666 mg TID with meals. Preferred in patients with significant hepatic impairment or those who cannot tolerate naltrexone.

Communication Scripts for Your Staff

When patients call about disulfiram availability, your staff can use this response framework:

1. Acknowledge the shortage: "There is a known supply issue with certain disulfiram presentations. We understand this is stressful."
2. Direct to medfinder: "Please try medfinder.com — it will search pharmacies near you to find which ones have your medication in stock."
3. Offer a callback: "If you've checked multiple pharmacies and still can't find it, call us back and we'll discuss next steps with your provider."

Documentation and Liability Considerations

When a patient is unable to continue disulfiram due to a shortage, document the supply barrier in the medical record. If you transition to an alternative agent, document informed consent for the new medication, any relevant contraindication screening (especially opioid use history for naltrexone), and the clinical rationale for the switch. This protects both the patient and the provider.

For more clinical detail on the shortage and transitioning strategies, see our full provider briefing on the disulfiram shortage for providers in 2026.